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Public Health 
Health Risks and Emerging Trends 
with the Use of Electronic Cigarettes 
Lucy Wagala, Austin Hopkins, Natalie Lennartz, Brian Heilbronner, Brittany L. Long, PharmD, 
Natalie DiPietro Mager, PharmD, MPH 
Abstract 
Cigarette smoking is associated with many health risks and 
complications. Despite smokers' strong desire to quit, most 
battle with nicotine withdrawal and relapse. Because elec-
tronic cigarettes Ce-cigarettes) do not contain tobacco, some 
believe them to be safer than traditional cigarettes and have 
used them as a replacement or adjunct nicotine source to 
prevent withdrawal symptoms. Electronic cigarettes are de-
signed to mimic traditional cigarettes and expel a vapor 
composed of nicotine, water, glycerol, propylene glycol and 
other flavorings. Many e-cigarette companies use appealing 
platforms, which promise smoking cessation and harm 
reduction, to attract consumers; however, several studies 
have found e-cigarettes actually contain ingredients that are 
harmful to one's health. Studies have demonstrated that the 
use of e-cigarettes can be toxic to patients' health if patients 
do not research the products they intend to purchase. The 
flavoring of e-cigarettes may be a major contributor to 
e-cigarette cytotoxicity. If flavoring and other cytotoxic con-
tents of e-cigarettes can be eliminated, e-cigarettes may be 
useful in smoking reduction and cessation. Many clinicians 
today support traditional forms of nicotine replacement ther-
apy for smoking cessation rather than e-cigarettes. Due to 
the lack of regulation and studies by the U.S. Food and Drug 
Administration, e-cigarettes may not be as safe as users may 
perceive and should not be a preferred product for smoking 
cessation therapy until they are further studied and regulat-
ed. 
Key Terms 
Electronic Cigarettes; Nicotine; Pharmacies; Safety; Smoking 
Cessation 
Introduction 
Cigarette smoking is linked to multiple, serious health risks. 
Smoking impairs almost every organ in the body, causes sev-
eral diseases, increases healthcare costs and negatively im-
pacts the overall health of people who choose to use these 
products.1 While only 18 percent of the U.S. population were 
smokers in 2012 compared to 42 percent in 1965, there are 
still about 42 million Americans who continue to smoke.2 In 
2012, about 21 percent of all American men and about 16 
percent of all American women smoked. Furthermore, smok-
ing is a problem among adolescents, and it is estimated that 
each day more than 3,200 teenagers smoke for the first 
time.3 This results in nearly 14 percent of high school stu-
dents and 4 percent of middle school students being consid-
ered as current cigarette smokers. 
Smoking not only impacts a person's health but also affects 
the public environment.4 Smoke contains carcinogens, toxic 
metals and poisonous gases that are harmful to not only the 
smoker but also to the people around the smoker. Addition-
ally, second-hand smoke harms the atmosphere by degrading 
air quality and significantly contributes to littering, where 
cigarette butts are listed as the most littered item. It is also 
extremely costly to clean up littering related to smoking.s For 
example, in places like San Francisco, it costs up to $10.7 mil-
lion to remove cigarette butts from public spaces each year. 
The production of cigarettes alone is also detrimental to the 
environment, as for every 300 cigarettes that are produced, 
one tree is consumed.s.6 Improper discarding of cigarettes 
has been found to cause destructive wildfires which leads to 
damaged properties, vegetation, forestry, animal habitats 
and death.6 
Smoking cessation can help decrease the risk of smoking-
related diseases and add years to past-smokers' lives.7 Ac-
cording to a survey by the Centers for Disease Control and 
Prevention (CDC) in 2010, almost 70 percent of adult smok-
ers said they wanted to quit smoking completely. Smokers in 
the beginning stages of quitting often experience severe 
withdrawal symptoms due to nicotine addiction.a Nicotine, 
the primary psychoactive chemical in tobacco, is highly ad-
dictive, and smokers who quit often experience intense with-
drawal symptoms including extreme nicotine cravings, de-
pression, anxiety, difficulty sleeping, nightmares, headaches, 
increased appetite and weight gain.9 Medications containing 
nicotine such as lozenges, gums and patches can help to de-
crease the withdrawal symptoms and cigarette cravings, 
when used correctly, and could potentially double a smoker's 
chances of quitting.a Some people have turned to e-cigarettes 
as a nicotine replacement or adjunct therapy option for 
smoking cessation.10 Electronic cigarettes provide patients 
with the sensation of smoking; however, what most people 
do not know is that e-cigarettes have not been proven safe or 
effective in smoking cessation. 
Hon Lik, a pharmacist and smoker in China, developed 
e-cigarettes in 2003 after his father died of lung cancer.11 
Electronic cigarettes were later introduced to the United 
States in late 2006 and early 2007. However, e-cigarettes did 
not become popular until 2013 when a number of large 
tobacco companies invested in their production.12 As a two-
packs-per-day smoker, Hon Lik developed e-cigarettes in 
hopes of producing a method that would help himself quit. In 
the past he had tried nicotine patches, but they failed to give 
him the "rush" associated with smoking cigarettes he 
enjoyed. Thus, e-cigarettes were designed to imitate "smoke 
without fire."13 
Electronic cigarettes vaporize a mixture of liquid nicotine, 
water, glycerol, propylene glycol and other flavorings.12 They 
consist of an atomizer, which heats the liquids into a vapor; a 
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cartridge, which holds the e-Iiquids; and a rechargeable bat-
tery, which powers the atomizer. Electronic cigarettes con-
tain no tobacco, odor or smoke. Most are designed to be used 
and appear as a cigarette so that when a user draws on it, 
visible vapor is produced while a light-emitting diode (LED) 
portrays a real cigarette glow. Aside from the traditional to-
bacco and menthol flavors, more than 200 other 
flavors, such as bubblegum and cherry, exist. Before using an 
e-cigarette, the user must first attach the cartridge.14 Most 
e-cigarettes are activated when a user inhales, causing the 
atomizer to heat the liquid and turn it into a vapor, while 
other e-cigarettes are activated with a switch. Inhalation of 
the vapor through the mouthpiece delivers nicotine to the 
user's lungs and, upon exhalation, gives an appearance simi-
lar to a cloud of smoke. 
Emerging Trends 
Electronic cigarette use has risen rapidly over the last few 
years. The number of adults in the United States who used an 
e-cigarette rose from 3.3 percent in 2010 to 8.5 percent in 
2013, and the number of current cigarette smokers who have 
used e-cigarettes has risen from 9.8 percent to 36.5 per-
cent.15 From 2013 to 2014, the number of high school stu-
dents who used an e-cigarette in the past month tripled to 
13.4 percent, and the number of high school students that 
have never used cigarettes, but have used e-cigarettes, in-
creased to an estimated 250,000.16 Marketing of e-cigarettes 
by tobacco companies is extensively aimed at youth under 
the age of 21 years, specifically high school students, where 
companies invest in advertising their products through mag-
azines, movies, sponsorship of concerts and auto races, and 
celebrity endorsements and researching youth behaviors to 
generate attracting themes.16-10 
Currently, only e-cigarettes marketed for therapeutic pur-
poses are regulated by the U.S. Food and Drug Administra-
tion (FDA) Center for Drug Evaluation and Research 
(CDER).19 Other tobacco products, such as cigarettes, smoke-
less tobacco and roll-your-own tobacco are currently regulat-
ed by the FDA Center of Tobacco Products (CTP). However, 
to address the public issue of unhealthy tobacco use, a rule 
named "Tobacco Products Deemed To Be Subject to the Food, 
Drug & Cosmetic Act" has been proposed by the FDA to ex-
pand its authority to regulate all products that are consid-
ered tobacco products, including e-cigarettes.20 State and 
local governments also have laws about tobacco products, 
which include prohibiting smoking and tobacco in public 
places, taxing tobacco products, enforcing Medicaid to cover 
smoking cessation programs and prohibiting the sale of 
flavored tobacco products.21 In 2006, Ohio instituted a 
statewide ban against tobacco requiring businesses and 
organizations to prohibit smoking.22 
Electronic Cigarettes: Cytotoxicity and Other Health 
Risks 
While e-cigarettes are becoming a popular alternative to to-
bacco cigarettes, many health professionals are wary in rec-
ommending these products to their patients primarily be-
cause e-cigarettes have not been proven safe for long-term 
use. 23 Common complaints from e-cigarette users are head-
ache, respiratory tract infection and changes in appetite. Up-
on initial investigation of e-cigarettes, they may appear to be 
a good alternative to traditional cigarettes. Most e-cigarette 
companies use the appealing platform of promising smoking 
cessation and harm reduction to attract consumers.Howev-
er, without knowing the long-term health risks associated 
with e-cigarettes, it can be difficult for a healthcare profes-
sional to provide any recommendation of e-cigarettes to both 
tobacco and non-tobacco users.24 
Farsalinos and colleagues performed a study to determine 
whether or not e-cigarettes are less harmful than tobacco 
cigarettes_25 They measured and compared the cytotoxic po-
tential of cigarette smoke and e-cigarette vapor extract on 
cultured myocardial cells. Additionally, they measured 
whether or not using a higher voltage (3.7 volts versus 4.7 
volts) has an effect on cytotoxicity of e-cigarette agents. Elec-
tronic cigarette and cigarette smoke samples were tested in 
vapor form, as this is the form most used by consumers. Cy-
totoxicity was defined as viability less than 70 percent based 
on a specific protocol (ISO 10993-5). This was only done on 
low voltage e-cigarette samples due to an insufficient num-
ber of high voltage samples to demonstrate a significant dif-
ference. 
The authors tested the vapor cytotoxicity of one cigarette 
smoke sample, 20 e-cigarette liquid samples and an 
e-cigarette base sample at five different concentrations: 100 
percent, 50 percent, 25 percent, 12.5 percent and 6.25 per-
cent.25 Table 1 demonstrates the myocardial cell viability at 
low voltage of the cigarette smoke sample, base sample and 
the four e-cigarette vapor extracts that demonstrated a cyto-
toxic effect. Most tobacco producing samples exhibited the 
lowest survival rates. The base sample, containing 50 percent 
propylene glycol, 50 percent glycerol and no nicotine or fla-
voring, was considered non-cytotoxic at any extract concen-
tration. Cigarette smoke was significantly more cytotoxic 
than e-cigarette samples with cytotoxicity exhibited at all 
concentrations above 6.25 percent. The most cytotoxic of the 
four samples was "El Toro Puros." Results of high voltage 
samples above 6.25 percent were not considered statistically 
significant due to the small amount of samples tested. The 
authors admitted the need to perform further studies, using 
more samples and more efficient atomizers, to determine the 
viability of e-cigarette use in higher voltage samples. Farsal-
inos and colleagues also suggested that flavoring, and the 
varying quantities of flavorings in liquids, may be a major 
contributor to e-cigarette cytotoxicity. Some flavorings are 
approved for use in food, but their effects when heated or 
evaporated are unknown. 
A study by Romagna and colleagues also suggested flavoring 
as a cause of cytotoxicity in e-cigarettes liquid.26 In the study, 
21 e-cigarette liquids were tested, and only one out of the 21 
liquids had cytotoxic properties when exposed to cultured 
mammalian fibroblasts. All samples were produced by the 
same manufacturer and had the same main ingredients 
(propylene glycol, glycerol and nicotine) in similar concen-
trations, leaving flavoring as the only contributor to varying 
cell viability. 
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Table 1. Myocardial Cell Viability in Cigarette Smoke and Electronic Cigarette Vapor Extracts at 3.7 volts (low 
voltage ).25 
Dilutions 
Samples 100% 50%1 25% 12.500/ri 6.25% 
Cinnamon-Cookies 64.8± 2.5% 100.8±2.0% 97.2± 2.9% 99.3± 1.7% 99.2± 3.8% 
El Toro Cigarillos-1 39.1±1.2% 52.5±1.8% 81.0± 2.0% 92.6± 0.4% 99.2± l.0% 
El Toro CigarilJos-Z 22.3±4.0% 66.9± 6.2% 104.1± 5.8% 109.9±6.0% 112.0± 8.8% 
El Toro Puros 2.2± 0.6%1 7.4± 3.9% 84.5±6.5% 115.3± l l.7% 111.9±7..lo/o 
Base Sample 105.1± 1.2% 103.5± 1.9% 101.3± 4.2% 100.7± 3.4% 100.4± 2.3% 
Cigarette smoke 3.9± 0.2%1 5.2 ± 0.81% 3.1± 0.2% 38.2± 0.6% 76.l) ± 2.0% 
Data comparing cytotoxicity between e-cigarettes and cigarette smoke was reported using mean± standard deviation. Data 
comparing e-cigarette samples was reported using a paired t-test. Among e-cigarette samples, an independent t-test was 
used to assess whether nicotine levels played a role in viability. A two tailed p value< 0.05 was considered statistically signif-
icant. All samples, besides the base, had p values <0.001 and were considered statistically significant. 
Studies evaluating the cytotoxicity of individual flavors in 
vapor form and the cytotoxicity of flavors at different 
concentrations may be essential in the production of safe 
e-cigarettes.21 Bahl and colleagues completed a study using 
embryonic and adult cells to compare the cytotoxicity of vari-
ous e-cigarette refill fluid flavors. They used three cell types: 
cells modeling the epiblast stage of human embryonic devel-
opment (hESC), mouse neural stem cells (mNSC) isolated 
from the brain of a newborn and human pulmonary fibro-
blasts (hPF) representing adult cells from one of the initial 
points of contact of inhaled e-cigarette aerosol. Thirty-four 
refill fluid samples of varying doses, flavorings and nicotine 
concentrations were compared in all cell types, and found to 
differ significantly in potency. Refill fluids used were ob-
tained from popular companies whose products are easily 
accessible to e-cigarette users online. Ninety-six well plates 
were filled with negative controls and refill solutions of vari-
ous doses (0.001%, 0.01%, 0.03%, 0.1%, 0.3% and 1%). Ta-
ble 2 shows the half maximal inhibitory concentration (!Cso) 
of the refill fluid product flavors that produced the most sig-
nificant results and are the most common humectants used 
in refill fluid . Vegetable glycerin (VG) and propylene glycol 
(PG) are the two humectants most often used in refill solu-
tions, and these were considered non-cytotoxic for both cell 
types. Menthol Artie (Freedom Smoke USA) and Caramel #40 
(Global Smoke) demonstrated the strongest cytotoxic effects 
on hPF cells. Cinnamon Ceylon was found to be the most po-
tent sample and the only one that produced strong cytotoxic 
effects on all three types of cells. The Bubblegum sample was 
tested and found to be non-cytotoxic. The authors warned 
that the cytotoxicity results achieved were potentially inac-
curate. This is because the study used doses of vapor that 
were 100 times lower than the actual doses consumers 
would use. Therefore, a flavor demonstrating no toxicity at a 
1 percent concentration, which was used in this study, may 
actually exhibit cytotoxicity when consumed at normal high 
doses such as 10 percent. 
The study then used high pressure liquid chromatography 
spectra and found that products of the same flavor varied in 
flavor peaks and cytotoxicity.27 For example, Butterscotch 
#30 and Butterscotch #29 had low toxicity and had fewer 
and shorter flavoring peaks (low chemical concentrations). 
In contrast, Butterscotch #20, which demonstrated cytotoxi-
city, had greater and higher flavor peaks (high chemical con-
centrations). These results demonstrate that companies are 
not always consistent with the contents of their products. 
Products of the same flavor from one manufacturer can vary 
in the amount of chemicals and, therefore, the levels of cyto-
toxicity. Additionally, stem cells from embryos and newborns 
were found to be more sensitive to refill solution than differ-
entiated adult lung cells; consequently, it will be essential in 
future studies for e-cigarette cytotoxicity to be tested during 
pregnancy and in multiple cell types. 
This study also examined the effects of nicotine on the cyto-
toxicity of e-cigarettes.27 In Table 2, the nicotine levels of the 
refill fluids and humectants are shown. Samples containing 
nicotine concentrations ranging from 0 to 24 mg/mL were 
used. Propylene glycol, VG, Caramel #26, Butterscotch #30, 
Menthol Artie, Butterscotch #20, Cinnamon Ceylon and Cara-
mel #21 contained 0 mg nicotine/mL; however, they differed 
in cytotoxicity. Propylene glycol, VG, Caramel #26, Butter-
scotch #30 and Menthol Artie were non-cytotoxic/low cyto-
toxicity while Butterscotch #20, Cinnamon Ceylon and Cara-
mel #21 were considered toxic. Bubblegum and Butterfinger 
#19 were considered to have no cytotoxicity or low cytotoxi-
city but contained 24 mg nicotine/ml. 
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This study demonstrates that in order to truly confirm the 
cytotoxicity of e-cigarettes additional studies will need to be 
completed with great caution.27 As this study only examined 
the end result of exposure, studies evaluating the reason for 
differences in cell survival may be beneficial. The results also 
demonstrate that high levels of nicotine do not correlate with 
high cytotoxicity in e-cigarettes, leaving the flavoring of 
e-cigarettes as the main cause of e-cigarette toxicity. 
Aside from flavoring, there are several other toxic substances 
present in e-cigarette cartridges at low levels.2s These sub-
stances include carbonyl compounds, volatile organic com-
pounds, nitrosamines, ultrafine particulate matter and heavy 
metals. Performing studies on the cytotoxicity of these addi-
tional agents is important because they are known to con-
tribute to various disease processes. Even the humectant 
propylene glycol, which is not cytotoxic in liquid form, has 
been found to contribute to allergic respiratory symptoms, 
and the safety of inhaling its vaporized form has not been 
tested in humans. By eliminating their cytotoxic flavors and 
other cytotoxic component, e-cigarettes may be able to con-
tribute safely to tobacco reduction and cessation. 
Ta bl 2 c . L e ;ytotox1c eve san dN' 1cotme c ontent o fV . arious R fllFl "dP d e I UI ro uct Fl avors. 27 
Refill fluid (Company) Nicotine (mg/ml) Cell Type 
hESCc mNSCtl hPFe 
Propylene glycol (FS-USA)a Low Low Low 
Vegetable Glycerin (FS·USA) Low Low Low 
Bubblegum #18 (FS-USA) 24 Low Low Low 
Butterscotch #30 (FS-USA) 0 Low Low Low 
Butterscotch #29 (FS-USA) 6 Low Low Low 
Caramel #26 (Freedom Smoke) 0 Low Low Low 
Caramel #27 (Freedom Smoke) 6 Low Low Low 
Caramel #28 (Freedom Smoke) 6 Low Low Low 
Caramel #40 (Global Smoke) 18 Moderate Low Moderate 
Butterfinger #19 (FS·USA) 24 Moderate Low Low 
Menthol Arctic (Freedom Smoke) 0 Moderate Low Moderate 
Vanilla Tahity (FS·USA) 0 Moderate Moderate Moderate 
Pure nicotine (FS-USA) 100 Moderate Moderate Moderate 
Caramel #21 (Freedom Smoke) 0 Moderate Moderate Moderate 
Arctic Menthol (Johnson Creek) 18 High Moderate Low 
Butterscotch #20 (FS·USA) 0 High Moderate Moderate 
Cinnamon Ceylon (FS·USA) 0 High High High 
Butterscotch #41 (Freedom Smoke)h 0 --- Moderate Moderate 
Refill products were considered to be non-cytotoxic or have low cytotoxicity if ICso>l %, moderate toxicity if IC50 was 0.1·1 %, 
and high cytotoxicity if ICS0<0.1 %. 
afreedom Smoke USA 
h8utterscotch #41 was only tested in mNSC and hPF because it was ordered and arrived from the manufacturer later in the 
experiment. 
c(e!ls modeling the epiblast stage of human embryonic development 
dMouse neural stem cells isolated from the brain of a newborn 
•Human pulmonary fibroblasts 
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Electronic Cigarettes: Examining Utility for Smoking 
Cessation Therapy 
In a prospective proof of concept six-month pilot study, Po-
losa and colleagues examined the effect of e-cigarettes on 
smoking reduction and cessation.29 Forty regular smokers 
(unwilling to quit) were invited to attend five study visits 
(baseline, week 4, week 8, week 12 and week 24) and follow-
up appointments at each visit. Adverse events and partici-
pants' opinions and acceptance of the product were also 
monitored. Smokers ranged from 18 to 60 years of age, 
smoked greater than or equal to 1S factory made cigarettes 
per day for at least the past 10 years and were not currently 
trying to quit smoking or hoping to do so in the next 30 days. 
At the baseline visit, participants were given a free 
e-cigarette kit and were instructed on how to use, charge and 
activate the e-cigarette. A four-week supply of 7.4 mg nico-
tine cartridges was also provided, and participants were 
trained on how to load them into the e-cigarette atomizer. 
Participants were allowed to use the e-cigarette at their own 
convenience throughout the day up to a maximum of four 
cartridges per day as recommended by the manufacturer. 
They were also instructed to complete a four-week study dia-
ry to record their use, the number tobacco cigarettes smoked 
and any adverse events. Subjects were invited to subsequent 
visits to receive more free supplies of cartridges and study 
diaries, to record their exhaled carbon monoxide (eCO) levels 
and to give back completed study diaries and unused prod-
ucts . At the final follow-up visit, participants reported prod-
uct usage (cartridges/day), number of tobacco cigarettes, 
and eCO levels and rated the degree of usefulness of the 
product. 
The product ratings of satisfaction, helpfulness in keeping 
them from smoking and whether they would recommend to 
a friend who wants to quit or reduce smoking were meas-
ured using a visual analogue scale (0 = completely unsatis-
fied, 10 = fully satisfied). Patients who spontaneously asked 
for assistance in quitting were provided with smoking cessa-
tion services but were excluded from the study. The majority 
(67.So/o) of participants were able to adhere to the program 
and returned for the final follow-up visit with an overall quit 
rate of 22.S percent. There was at least a SO percent reduc-
tion in cigarette smoking in 32.S percent of participants. 
Overall SS percent of participants exhibited reduction or 
smoking cessation.29 The study suggested that the positive 
effect of e-cigarettes could have been due to their ability to 
replace some of the rituals associated with smoking (e.g., 
hand-to-mouth action of smoking). E-cigarette use was not 
found to produce increased CO levels. Serious adverse events 
or events causing unscheduled visits to a healthcare provider 
did not occur. The most frequent adverse events were mouth 
irritation (20.6%), throat irritation (32.4%) and dry cough 
(32.4%) possibly due to the low toxicity of propylene glycol. 
However, these adverse events subsided with time, and par-
ticipants were satisfied with the product. Side effects such as 
depression, anxiety, insomnia, irritability, hunger and consti-
pation that are normally present in smoking cessation trials 
with drugs for nicotine dependence were absent. 
The authors admitted that the study was small and uncon-
trolled; therefore, the results could have been due to chance 
and should be interpreted with caution.29 Additionally, the 
study's design should not be considered as an ordinary ces-
sation study because the design included smokers who were 
unwilling to quit and used e-cigarettes. Based on this study, 
e-cigarettes should not be compared to other smoking cessa-
tion products, and the absence of withdrawal symptoms and 
adverse effects should be considered with caution, given that 
the authors did not study these variables rigorously. 
Conclusion from Selected Studies on Electronic Cigarettes 
These five studies demonstrate that the use of e-cigarettes is 
not yet safe and healthy for the public.25-29 There are still 
many factors including toxicity and efficacy in smoking ces-
sation that need to be studied further. An article by Simon 
Chapman, professor of public health at the University of Syd-
ney, stresses many mistakes have been made with the way 
tobacco has been sold and marketed.23 In order to avoid the 
same mistakes with e-cigarettes, early caution should be tak-
en. Chapman suggests scheduling e-cigarettes and creating 
access through pharmacies with a permit or prescription as a 
way for them to be overseen for quality and safety. This 
tighter control would allow e-cigarettes to be carefully moni-
tored through research, and their availability to be relaxed or 
tightened as evidence of benefits and/or harms develop. 
Clinical Applications and the Role of the Pharmacist 
As of now the FDA has not completely studied and evaluated 
e-cigarettes and cannot state if there is any therapeutic bene-
fit from the use of these products. Currently, only e-cigarettes 
that are marketed for or claim a therapeutic purpose such as 
smoking cessation are being regulated.30 The FDA issued a 
proposition that would allow the agency's tobacco authority 
to cover additional products that meet the legal definition of 
a tobacco product, such as e-cigarettes and any other prod-
ucts containing tobacco derivatives such as nicotine.30,19 
Before initiating any form of smoking cessation, pharmacists 
should consider using the "SAs" approach. This involves 
asking the patient about his or her current tobacco use, 
advising them on the importance of quitting and the 
health benefits that come with smoking cessation, and 
assessing if the patient is willing and ready to quit. Once 
the patient is ready, the pharmacist should assist the patient 
in selecting and beginning smoking cessation therapy and 
arranging follow-up sessions to help monitor and encour-
age the patient's progress. A first-line treatment to smoking 
cessation for most patients is nicotine replacement therapy 
(NRT).31 Other first-line treatments include prescription 
products such as varenicline and bupropion SR. On the mar-
ket, there are a number of NRT products designed to help 
patients end their need for nicotine. Available NRT products 
include gums, lozenges, nasal sprays, inhalers and patches. 
Each of these products have advantages and disadvantages 
which the patient should discuss with a pharmacist in order 
to determine which product is right for them.32 As of now, e-
cigarettes have not been formally classified as a NRT prod-
uct, but there is continuing research to determine if 
e-cigarettes would qualify.19 
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From the presented studies and evidence, the use of 
e-cigarettes can be toxic to the health of patients, and with-
out regulation to standardize e-cigarettes, it may be difficult 
to discern which products are safe.Jo Although, there are no 
official counseling guidelines for e-cigarettes, it is still im-
portant that pharmacists use available knowledge to inform 
patients on the effects of e-cigarettes. Most e-cigarettes do 
not contain a tamper resistant mechanism, which has result-
ed in children overdosing on nicotine by consuming the con-
centrated nicotine liquid. Likewise, various liquids cause 
damage to cells, and certain e-cigarette devices, especially 
ones that are higher in voltage, can contribute additional 
harm.2s In comparison to traditional tobacco based ciga-
rettes, it is not accurate to say that e-cigarettes are better or 
worse. This is because e-cigarettes are not being formally 
regulated in the same way.19 Patients who are looking to 
switch from traditional tobacco cigarettes to e-cigarettes as a 
form of NRT should be informed about the consequences of 
using e-cigarettes and their effects on health; an example 
being that certain nicotine liquids and e-cigarettes can cause 
more cytotoxicity when compared to other brands of 
e-cigarettes.27,30,32 If a patient wants to quit smoking ciga-
rettes, pharmacists should make recommendations on safer 
established methods, such as NRT products, before suggest-
ing e-cigarettes. Patients already using e-cigarettes as a form 
of smoking cessation should be encouraged to switch to es-
tablished methods or, at a minimum, invest in products that 
progressively contain less and less nicotine, eventually se-
ceding from all nicotine and tobacco containing prod-
ucts.25,30,31 Utilizing the above counseling points, regulated 
forms of NRT, or referral to a physician who can prescribe a 
prescription based smoking cessation therapy, would all be 
safer options than using an e-cigarette.27,30 
Conclusion 
Presently, there have been studies to show that certain 
e-cigarette and nicotine liquid brands are safer than the 
traditional e-cigarette, but that does not mean e-cigarettes in 
general are completely safe. The FDA has listed a number of 
adverse effects that have been attributed to the chronic use 
of e-c;igarettes including, but not limited to, chronic heart 
failure, pneumonia and seizures. Additional studies, the crea-
tion of standards and regulating e-cigarettes like tobacco are 
important next steps. Unfortunately, the FDA has not institut-
ed such regulations but is currently working on extending 
the e-cigarette classification to be in the same category as 
traditional tobacco products. If a standard and safe 
e-cigarette is created, this could add another potentially safer 
NRT option for smoking cessation. 
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